Lonza Group AG

Swiss Stock Exchange:LONN.SW

Sector

🏥 Health Care

Industries

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 49.39 B

Share Price

USD 684.56

Avg Daily Volume

174,942

Change (1 day)

0.23%

Change (1 year)

27.07%

Change (YTD)

15.54%

Lonza Group AG EBIT for the year ending December 31, 2024: USD 985.47 M

Lonza Group AG EBIT is USD 985.47 M for the year ending December 31, 2024, a -8.92% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Lonza Group AG EBIT for the year ending December 31, 2023 was USD 1.08 B, a -34.13% change year over year.
Lonza Group AG EBIT for the year ending December 31, 2022 was USD 1.64 B, a 74.26% change year over year.
Lonza Group AG EBIT for the year ending December 31, 2021 was USD 942.65 M, a -2.97% change year over year.
Lonza Group AG EBIT for the year ending December 31, 2020 was USD 971.46 M, a 17.49% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Swiss Stock Exchange: LONN.SW

Lonza Group AG

CEO	Dr. Wolfgang Wienand Ph.D.
IPO Date	Nov. 1, 1999
Location	Switzerland
Headquarters	Muenchensteinerstrasse 38
Employees	17,995
Sector	🏥 Health Care
Industries Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.